Foekens J A, Portengen H, van Driel J, van Putten W L, Haije W G, Klijn J G
Division of Endocrine Oncology, Biochemistry, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
J Steroid Biochem. 1988 Jun;29(6):571-4. doi: 10.1016/0022-4731(88)90153-7.
We have compared a new enzyme immunoassay for progesterone receptors (Abbott PgR-EIA, monoclonal) with our standard radioligand binding-assay (PgR-RBA). For both assays cytosols were freshly prepared from human breast cancer specimens that had been stored frozen for up to 1 year, and predominantly tissues were used which contained critically low amounts of progesterone receptors. A highly significant correlation was observed between the PgR-EIA and PgR-RBA (Spearman: Rs = 0.85, n = 100). Using a cut-off point of 10 fmol PgR/mg protein, 87% of the values were in accordance with each other (52% negative, and 35% positive in both assays), whereas 13% scored positive (median: 16, range 11-38 fmol PgR/mg protein) in one assay and negative (median: 7, range 0-10 fmol PgR/mg protein) in the other. Also in cytosols from human ovarian and endometrial carcinoma tissues immunoreactive PgR could be detected, and significant correlations with PgR-RBA were observed (Rs = 0.94, n = 6) for both tissues.
我们将一种新的孕酮受体酶免疫测定法(雅培孕酮受体酶免疫测定法,单克隆)与我们的标准放射配体结合测定法(孕酮受体放射配体结合测定法)进行了比较。对于这两种测定法,细胞溶质均从冷冻保存长达1年的人乳腺癌标本中新鲜制备,并且主要使用孕酮受体含量极低的组织。在孕酮受体酶免疫测定法和孕酮受体放射配体结合测定法之间观察到高度显著的相关性(斯皮尔曼:Rs = 0.85,n = 100)。使用10 fmol孕酮受体/毫克蛋白质的临界值,87% 的值彼此一致(两种测定法中52% 为阴性,35% 为阳性),而13% 在一种测定法中为阳性(中位数:16,范围11 - 38 fmol孕酮受体/毫克蛋白质),在另一种测定法中为阴性(中位数:7,范围0 - 10 fmol孕酮受体/毫克蛋白质)。在人卵巢癌和子宫内膜癌组织的细胞溶质中也能检测到免疫反应性孕酮受体,并且在这两种组织中均观察到与孕酮受体放射配体结合测定法有显著相关性(Rs = 0.94,n = 6)。